Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

The tainted heparin story: an update.

Guerrini M, Shriver Z, Bisio A, Naggi A, Casu B, Sasisekharan R, Torri G.

Thromb Haemost. 2009 Nov;102(5):907-11. doi: 10.1160/TH09-02-0079.

PMID:
19888527
2.

From crisis to opportunity: a perspective on the heparin crisis.

Sasisekharan R, Shriver Z.

Thromb Haemost. 2009 Nov;102(5):854-8. doi: 10.1160/TH09-02-0083. Review. No abstract available.

PMID:
19888519
3.

[Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].

Lindahl U.

Lakartidningen. 2008 Sep 24-30;105(39):2660-1. Swedish. No abstract available.

PMID:
18846871
4.

Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.

McMahon AW, Pratt RG, Hammad TA, Kozlowski S, Zhou E, Lu S, Kulick CG, Mallick T, Dal Pan G.

Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):921-33. doi: 10.1002/pds.1991.

PMID:
20661880
5.

Tainted heparin crisis tested FDA's investigative skills.

Lavine G.

Am J Health Syst Pharm. 2009 Feb 1;66(3):210-1. doi: 10.2146/news090013. No abstract available.

PMID:
19179633
6.

Contaminated heparin associated with adverse clinical events and activation of the contact system.

Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R.

N Engl J Med. 2008 Jun 5;358(23):2457-67. doi: 10.1056/NEJMoa0803200. Epub 2008 Apr 23. Erratum in: N Engl J Med. 2010 Mar 18;362(11):1056.

7.

Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.

Viskov C, Bouley E, Hubert P, Martinez C, Herman F, Jeske W, Hoppensteadt D, Walenga JM, Fareed J.

Clin Appl Thromb Hemost. 2009 Jul-Aug;15(4):395-401. doi: 10.1177/1076029609338710. Epub 2009 Jul 17.

PMID:
19617248
8.

Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.

Ramacciotti E, Clark M, Sadeghi N, Hoppensteadt D, Thethi I, Gomes M, Fareed J.

Clin Appl Thromb Hemost. 2011 Apr;17(2):126-35. doi: 10.1177/1076029610392214. Epub 2011 Feb 1. Review.

PMID:
21288929
9.

A chemical killer unmasked.

Perkel JM.

Anal Chem. 2008 Jul 1;80(13):4789-90. No abstract available.

PMID:
18609746
10.

Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.

McKee J, Bairstow S, Szabo C, Ray J, Wielgos T, Hu P, Chess E, Nordhaus M, Hai T, Campbell J, Donovan S, Viseux N, Riedel N, Cammack J, Johnson R.

J Clin Pharmacol. 2010 Oct;50(10):1159-70. doi: 10.1177/0091270009355158. Epub 2010 Feb 10.

PMID:
20147614
11.

[Contaminated heparins].

Monneret C.

Ann Pharm Fr. 2008 Aug;66(4):212-5. doi: 10.1016/j.pharma.2008.07.004. Epub 2008 Sep 9. French.

PMID:
18847567
12.

Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.

Clark M, Hoppensteadt D, Walenga J, Myers L, Cunanan J, Jeske W, Adiguzel C, Iqbal O, Fareed J.

Int Angiol. 2008 Oct;27(5):370-6.

PMID:
18974698
13.

[NMR analysis of a contaminant in heparin].

Yamaguchi H, Shinagawa M, Shimba N, Miyano H, Suzuki E.

Yakugaku Zasshi. 2008 Oct;128(10):1513-5. Japanese.

14.

Lessons learned from the contamination of heparin.

Liu H, Zhang Z, Linhardt RJ.

Nat Prod Rep. 2009 Mar;26(3):313-21. doi: 10.1039/b819896a. Epub 2009 Jan 19. Review.

15.

Contaminated heparin preparations, severe adverse events and the contact system.

Ramacciotti E, Wahi R, Messmore HL.

Clin Appl Thromb Hemost. 2008 Oct;14(4):489-91. doi: 10.1177/1076029608324291. No abstract available.

PMID:
18815138
16.

Heparin sodium compliance to the new proposed USP monograph: elucidation of a minor structural modification responsible for a process dependent 2.10 ppm NMR signal.

Mourier PA, Guichard OY, Herman F, Viskov C.

J Pharm Biomed Anal. 2011 Jan 25;54(2):337-44. doi: 10.1016/j.jpba.2010.09.011. Epub 2010 Sep 18.

PMID:
20934294
17.

Contaminants in heparins: are all facts known?

Fareed J, Hoppensteadt DA, Ramacciotti E, Hull RD.

Clin Appl Thromb Hemost. 2010 Jun;16(3):242-3. doi: 10.1177/1076029610365507. No abstract available.

PMID:
20547552
18.

Contaminated heparin.

Kakkar AK, Bonnefoi M.

N Engl J Med. 2008 Sep 18;359(12):1292-3; author reply 1293. No abstract available.

PMID:
18810795
19.

Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.

Warkentin TE, Greinacher A.

Expert Opin Drug Saf. 2009 Mar;8(2):129-44. doi: 10.1517/14740330902778180 . Review.

PMID:
19309242
20.

Contaminants in heparin.

Hull R, Walenga J.

Clin Appl Thromb Hemost. 2011 Apr;17(2):125. doi: 10.1177/1076029610397942. No abstract available.

PMID:
21406418

Supplemental Content

Support Center